Press Releases Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-17 EDT			5-day change	1st Jan Change
0.554 ^USD	+10.34%		+5.50%	-28.97%

04-25	Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	CI
03-14	Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	03-28	AQ
Purple Biotech : Immediate Report	03-06	PU
6K:Fourth Quarter and Full-Year 2023 Financial Results	03-05	PU
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	03-05	AQ
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	02-27	AQ
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	02-13	AQ
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	12-14	AQ
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	11-30	AQ
Purple Biotech Reports Third Quarter 2023 Financial Results	11-21	AQ
Purple Biotech Fortifies NT219 Patent Protection	11-02	AQ
Purple Biotech : Other Report or Announcement	23-10-31	PU
Purple Biotech : Immediate report on other matter	23-10-30	PU
Purple Biotech : Other Report or Announcement	23-10-19	PU
Purple Biotech : Form of Securities Purchase Agreement - Form 6-K	23-10-19	PU
Purple Biotech Announces $5 Million Registered Direct Offering	23-10-17	AQ
Purple Biotech : Immediate Report	23-10-17	PU
Purple Biotech : Immediate Report	23-10-13	PU
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action	23-10-06	AQ
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer	23-10-03	AQ
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023	23-09-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Press Releases

Filters